Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Behavioral and Brain Functions
Published in: Behavioral and Brain Functions 1/2012

Open Access 01-12-2012 | Research

The gamma-aminobutyric acid type B (GABAB) receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accumbens

Authors: Zhenyu Fu, Hongfa Yang, Yuqiang Xiao, Gang Zhao, Haiyan Huang

Published in: Behavioral and Brain Functions | Issue 1/2012

Login to get access

Abstract

Background

Repeated morphine exposure can induce behavioral sensitization. There are evidences have shown that central gamma-aminobutyric acid (GABA) system is involved in morphine dependence. However, the effect of a GABAB receptor agonist baclofen on morphine-induced behavioral sensitization in rats is unclear.

Methods

We used morphine-induced behavioral sensitization model in rat to investigate the effects of baclofen on behavioral sensitization. Moreover, dopamine release in the shell of the nucleus accumbens was evaluated using microdialysis assay in vivo.

Results

The present study demonstrated that morphine challenge (3 mg/kg, s.c.) obviously enhanced the locomotor activity following 4-day consecutive morphine administration and 3-day withdrawal period, which indicated the expression of morphine sensitization. In addition, chronic treatment with baclofen (2.5, 5 mg/kg) significantly inhibited the development of morphine sensitization. It was also found that morphine challenge 3 days after repeated morphine administration produced a significant increase of extracellular dopamine release in nucleus accumbens. Furthermore, chronic treatment with baclofen decreased the dopamine release induced by morphine challenge.

Conclusions

Our results indicated that gamma-aminobutyric acid system plays an important role in the morphine sensitization in rat and suggested that behavioral sensitization is a promising model to study the mechanism underlying drug abuse.
Appendix
Available only for authorised users
Literature
1.
McDaid J, Dallimore JE, Mackie AR, Napier TC: Changes in accumbal and pallidal pcreb and deltafosb in morphine-sensitized rats: correlations with receptor-evoked electrophysiological measures in the ventral pallidum. Neuropsychopharmacology. 2006, 31: 1212-1226.PubMedCentralPubMed
2.
Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993, 18: 247-291.CrossRefPubMed
3.
Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, Fratta W: An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev. 2007, 53: 1-16. 10.1016/j.brainresrev.2006.05.003.CrossRefPubMed
4.
Contet C, Filliol D, Matifas A, Kieffer BL: Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity. Neuropharmacology. 2008, 54: 475-486. 10.1016/j.neuropharm.2007.10.015.CrossRefPubMed
5.
Narita M, Suzuki M, Kuzumaki N, Miyatake M, Suzuki T: Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann N Y Acad Sci. 2008, 1141: 96-104. 10.1196/annals.1441.032.CrossRefPubMed
6.
Li JX, Zhang Q, Liang JH: Valproate prevents the induction, but not the expression of morphine sensitization in mice. Behav Brain Res. 2004, 152: 251-257. 10.1016/j.bbr.2003.10.006.CrossRefPubMed
7.
Listos J, Talarek S, Poleszak E, Wrobel A, Fidecka S: Attenuating effect of adenosine receptor agonists on the development of behavioral sensitization induced by sporadic treatment with morphine. Pharmacol Biochem Behav. 2011, 98: 356-361. 10.1016/j.pbb.2011.01.019.CrossRefPubMed
8.
Spanagel R, Sillaber I, Zieglgansberger W, Corrigall WA, Stewart J, Shaham Y: Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology (Berl). 1998, 139: 391-401. 10.1007/s002130050730.CrossRef
9.
Corominas-Roso M, Roncero C, Bruguera E, Casas M: the dopaminergic system and addictions. Rev Neurol. 2007, 44: 23-31.PubMed
10.
Narita M, Funada M, Suzuki T: Regulations of opioid dependence by opioid receptor types. Pharmacol Ther. 2001, 89: 1-15. 10.1016/S0163-7258(00)00099-1.CrossRefPubMed
11.
Spanagel R, Heilig M: Addiction and its brain science. Addiction. 2005, 100: 1813-1822. 10.1111/j.1360-0443.2005.01260.x.CrossRefPubMed
12.
McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ: Deltafosb: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res. 2004, 132: 146-154.CrossRefPubMed
13.
De Vries TJ, Shippenberg TS: Neural systems underlying opiate addiction. J Neurosci. 2002, 22: 3321-3325.PubMed
14.
Willuhn I, Wanat MJ, Clark JJ, Phillips PE: Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci. 2010, 3: 29-71. 10.1007/7854_2009_27.PubMedCentralCrossRefPubMed
15.
Narita M, Kato H, Miyoshi K, Aoki T, Yajima Y, Suzuki T: Treatment for psychological dependence on morphine: usefulness of inhibiting nmda receptor and its associated protein kinase in the nucleus accumbens. Life Sci. 2005, 77: 2207-2220. 10.1016/j.lfs.2005.04.015.CrossRefPubMed
16.
Dayan P: Dopamine, reinforcement learning, and addiction. Pharmacopsychiatry. 2009, 42 (Suppl 1): S56-S65.CrossRefPubMed
17.
Filip M, Frankowska M: Gaba(b) receptors in drug addiction. Pharmacol Rep. 2008, 60: 755-770.PubMed
18.
Tyacke RJ, Lingford-Hughes A, Reed LJ, Nutt DJ: Gabab receptors in addiction and its treatment. Adv Pharmacol. 2010, 58: 373-396.CrossRefPubMed
19.
Van den Oever MC, Lubbers BR, Goriounova NA, Li KW, Van der Schors RC, Loos M, Riga D, Wiskerke J, Binnekade R, Stegeman M, Schoffelmeer AN, Mansvelder HD, Smit AB, De Vries TJ, Spijker S: Extracellular matrix plasticity and gabaergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking. Neuropsychopharmacology. 2010, 35: 2120-2133. 10.1038/npp.2010.90.PubMedCentralCrossRefPubMed
20.
Haney M, Hart CL, Foltin RW: Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology. 2006, 31: 1814-1821. 10.1038/sj.npp.1300999.CrossRefPubMed
21.
Paterson NE, Froestl W, Markou A: The gabab receptor agonists baclofen and cgp44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl). 2004, 172: 179-186. 10.1007/s00213-003-1637-1.CrossRef
22.
Knapp DJ, Overstreet DH, Breese GR: Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res. 2007, 31: 582-595.PubMedCentralCrossRefPubMed
23.
Bartoletti M, Gubellini C, Ricci F, Gaiardi M: Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine. Behav Pharmacol. 2005, 16: 553-558. 10.1097/01.fbp.0000179279.98029.e9.CrossRefPubMed
24.
Madhavan A, Bonci A, Whistler JL: Opioid-induced gaba potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area. J Neurosci. 2010, 30: 14029-14035. 10.1523/JNEUROSCI.3366-10.2010.PubMedCentralCrossRefPubMed
25.
Woodward RM, Polenzani L, Miledi R: Characterization of bicuculline/baclofen-insensitive (rho-like) gamma-aminobutyric acid receptors expressed in xenopus oocytes. Ii. Pharmacology of gamma-aminobutyric acida and gamma-aminobutyric acidb receptor agonists and antagonists. Mol Pharmacol. 1993, 43: 609-625.PubMed
26.
Wei XL, Su RB, Wu N, Lu XQ, Zheng JQ, Li J: Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats. Eur Neuropsychopharmacol. 2007, 17: 790-799. 10.1016/j.euroneuro.2007.04.001.CrossRefPubMed
27.
Karasawa J, Kotani M, Kambe D, Chaki S: Ampa receptor mediates mglu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell. Neurochem Int. 2010, 57: 615-619. 10.1016/j.neuint.2010.07.011.CrossRefPubMed
28.
Maccioni P, Bienkowski P, Carai MA, Gessa GL, Colombo G: Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in sardinian alcohol-preferring (sp) rats. Drug Alcohol Depend. 2008, 95: 284-287. 10.1016/j.drugalcdep.2008.02.006.CrossRefPubMed
29.
Weerts EM, Froestl W, Kaminski BJ, Griffiths RR: Attenuation of cocaine-seeking by gaba b receptor agonists baclofen and cgp44532 but not the gaba reuptake inhibitor tiagabine in baboons. Drug Alcohol Depend. 2007, 89: 206-213. 10.1016/j.drugalcdep.2006.12.023.PubMedCentralCrossRefPubMed
30.
Fattore L, Spano MS, Cossu G, Scherma M, Fratta W, Fadda P: Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. Eur Neuropsychopharmacol. 2009, 19: 487-498. 10.1016/j.euroneuro.2009.01.007.CrossRefPubMed
31.
Le Foll B, Wertheim CE, Goldberg SR: Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neurosci Lett. 2008, 443: 236-240. 10.1016/j.neulet.2008.07.074.PubMedCentralCrossRefPubMed
32.
Bartoletti M, Colantoni A, De Luca V, Gaiardi M: Single and repeated baclofen treatment attenuates the discriminative stimulus effects of morphine in rats. Pharmacol Biochem Behav. 2010, 97: 279-283. 10.1016/j.pbb.2010.08.011.CrossRefPubMed
33.
Spano MS, Fattore L, Fratta W, Fadda P: The gabab receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology. 2007, 52: 1555-1562. 10.1016/j.neuropharm.2007.02.012.CrossRefPubMed
34.
Xi ZX, Stein EA: Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther. 1999, 290: 1369-1374.PubMed
35.
Fadda P, Scherma M, Fresu A, Collu M, Fratta W: Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse. 2003, 50: 1-6. 10.1002/syn.10238.CrossRefPubMed
36.
Bexis S, Ong J, White J: Attenuation of morphine withdrawal signs by the gaba(b) receptor agonist baclofen. Life Sci. 2001, 70: 395-401. 10.1016/S0024-3205(01)01485-0.CrossRefPubMed
37.
Diaz SL, Barros VG, Antonelli MC, Rubio MC, Balerio GN: Morphine withdrawal syndrome and its prevention with baclofen: autoradiographic study of mu-opioid receptors in prepubertal male and female mice. Synapse. 2006, 60: 132-140. 10.1002/syn.20279.CrossRefPubMed
38.
Woo SH, Kim HS, Yun JS, Lee MK, Oh KW, Seong YH, Oh SK, Jang CG: Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity. Pharmacol Res. 2001, 43: 335-340. 10.1006/phrs.2000.0789.CrossRefPubMed
39.
Bartoletti M, Ricci F, Gaiardi M: A gaba(b) agonist reverses the behavioral sensitization to morphine in rats. Psychopharmacology (Berl). 2007, 192: 79-85. 10.1007/s00213-006-0693-8.CrossRef
40.
Leite-Morris KA, Fukudome EY, Shoeb MH, Kaplan GB: Gaba(b) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. J Pharmacol Exp Ther. 2004, 308: 667-678.CrossRefPubMed
41.
Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009, 330: 468-475. 10.1124/jpet.108.150011.PubMedCentralCrossRefPubMed
42.
Chefer VI, Shippenberg TS: Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacology. 2009, 34: 887-898. 10.1038/npp.2008.128.PubMedCentralCrossRefPubMed
43.
Zarrindast MR, Heidari-Darvishani A, Rezayof A, Fathi-Azarbaijani F, Jafari-Sabet M, Hajizadeh-Moghaddam A: Morphine-induced sensitization in mice: changes in locomotor activity by prior scheduled exposure to gabaa receptor agents. Behav Pharmacol. 2007, 18: 303-310. 10.1097/FBP.0b013e3282186baa.CrossRefPubMed
44.
Li JX, Zhao WL, Liang JH: Effects of carbamazepine on morphine-induced behavioral sensitization in mice. Brain Res. 2004, 1019: 77-83. 10.1016/j.brainres.2004.05.082.CrossRefPubMed
45.
Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry. 1999, 4: 512-523. 10.1038/sj.mp.4000575.CrossRefPubMed
46.
Kalivas PW, Pierce RC, Cornish J, Sorg BA: A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol. 1998, 12: 49-53. 10.1177/026988119801200107.CrossRefPubMed
47.
Phillips AG, Di Ciano P: Behavioral sensitization is induced by intravenous self-administration of cocaine by rats. Psychopharmacology (Berl). 1996, 124: 279-281. 10.1007/BF02246669.CrossRef
48.
Piazza PV, Deminiere JM, le Moal M, Simon H: Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res. 1990, 514: 22-26. 10.1016/0006-8993(90)90431-A.CrossRefPubMed
49.
Covington HE, Miczek KA: Repeated social-defeat stress, cocaine or morphine. Effects on behavioral sensitization and intravenous cocaine self-administration “binges”. Psychopharmacology (Berl). 2001, 158: 388-398. 10.1007/s002130100858.CrossRef
50.
Powell KR, Holtzman SG: Parametric evaluation of the development of sensitization to the effects of morphine on locomotor activity. Drug Alcohol Depend. 2001, 62: 83-90. 10.1016/S0376-8716(00)00167-8.CrossRefPubMed
51.
Nestler EJ: Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci. 2004, 25: 210-218. 10.1016/j.tips.2004.02.005.CrossRefPubMed
52.
Pierce RC, Kumaresan V: The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci Biobehav Rev. 2006, 30: 215-238. 10.1016/j.neubiorev.2005.04.016.CrossRefPubMed
53.
Pinto A, Jankowski M, Sesack SR: Projections from the paraventricular nucleus of the thalamus to the rat prefrontal cortex and nucleus accumbens shell: ultrastructural characteristics and spatial relationships with dopamine afferents. J Comp Neurol. 2003, 459: 142-155. 10.1002/cne.10596.CrossRefPubMed
Metadata
Title
The gamma-aminobutyric acid type B (GABAB) receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accumbens
Authors
Zhenyu Fu
Hongfa Yang
Yuqiang Xiao
Gang Zhao
Haiyan Huang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Behavioral and Brain Functions / Issue 1/2012
Electronic ISSN: 1744-9081
DOI
https://doi.org/10.1186/1744-9081-8-20

Other articles of this Issue 1/2012

Behavioral and Brain Functions 1/2012 Go to the issue

Research

Activation of dorsolateral prefrontal cortex in a dual neuropsychological screening test: An fMRI approach

Research

A dual task priming investigation of right hemisphere inhibition for people with left hemisphere lesions

Research

Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer's disease is dependent on the psychosis phenotype

Research

The Influence of verbalization on the pattern of cortical activation during mental arithmetic

Research

Apathy symptoms modulate motivational decision making on the Iowa gambling task

Research

Marine omega-3 polyunsaturated fatty acids induce sex-specific changes in reinforcer-controlled behaviour and neurotransmitter metabolism in a spontaneously hypertensive rat model of ADHD